Person profile

Public information reviewed

Cynthia Smith

Board role

Director · Tvardi Therapeutics, Inc. (NASDAQ: TVRD)

Board role

Director · AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO)

Board role

Director · Protara Therapeutics, Inc. (NASDAQ: TARA)

Board role

Director · Spero Therapeutics, Inc. (NASDAQ: SPRO)

Board role

Director · Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Tvardi Therapeutics, Inc. (NASDAQ: TVRD)

Director · Current mandate

Director
FollowSave PDF
More
Reports & analysis (Check report directory)Alpha Eval
Evidence records
15
Profile ownership
Not yet claimed
Record reviewed
May 16, 2026
View evidence

Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
55 current organizations shown on this profile
Board positions
55 supported by public sources, 0 supplied by the profile owner
Committee roles
3Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Cynthia Smith is a biotechnology executive with over 20 years of pharmaceutical industry experience. She served as Chief Commercial Officer of ZS Pharma through its IPO and acquisition by Astra Zeneca. She previously held leadership roles at Merck and the White House Office of Management and Budget. She holds a B.A., M.S. in public policy, and MBA from Wharton.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Tvardi Therapeutics, Inc.

2025-01-01 · current

Confirmed by public sourceView source

Director

AGIOS PHARMACEUTICALS, INC.

2022-01-01 · current

Confirmed by public sourceView source

Director

Protara Therapeutics, Inc.

2021-01-01 · current

Confirmed by public sourceView source

Director

Spero Therapeutics, Inc.

2019-01-01 · current

Confirmed by public sourceView source

Director

Akebia Therapeutics, Inc.

2018-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

AGIOS PHARMACEUTICALS, INC.

Open AGIOS PHARMACEUTICALS, INC. profile →

Director at AGIOS PHARMACEUTICALS, INC.

2022-01-01 → End not stated

current · source reported

Observed: 2026-09-25

AGIOS PHARMACEUTIC…AGIOS PHARMACEUTICALS, INC.Akebia Therapeutic…Akebia Therapeutics, Inc.Protara Therapeuti…Protara Therapeutics, Inc.Spero Therapeutics…Spero Therapeutics, Inc.Tvardi Therapeutic…Tvardi Therapeutics, Inc.Cynthia Smith

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingTVRD DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 2 · Sec FilingAKBA DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingSPRO DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 4 · Sec FilingTARA DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 5 · Sec FilingAGIO DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:cynthia-smith
Record version
public-0

Published evidence records

15 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. TVRD DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Tvardi Therapeutics, Inc. · Claim reviewed: May 16, 2026

  3. AKBA DEF 14A director slate

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Compensation, Research/Innovation · Claim reviewed: May 15, 2026

  4. Open source

    sec proxy · Source published: Apr 29, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Akebia Therapeutics, Inc. · Claim reviewed: May 16, 2026

  5. SPRO DEF 14A director slate

    sec filing · Source published: Apr 28, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Compensation · Claim reviewed: May 16, 2026

  6. Open source

    sec proxy · Source published: Apr 28, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Spero Therapeutics, Inc. · Claim reviewed: May 16, 2026

  7. TARA DEF 14A director slate

    sec filing · Source published: Apr 25, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Compensation · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  8. AGIO DEF 14A director slate

    sec filing · Source published: Apr 25, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026

  9. Open source

    sec proxy · Source published: Apr 25, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at AGIOS PHARMACEUTICALS, INC. · Claim reviewed: May 16, 2026

  10. Open source

    sec proxy · Source published: Apr 25, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Protara Therapeutics, Inc. · Claim reviewed: May 16, 2026

  11. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Tvardi Therapeutics, Inc. · Claim reviewed: May 16, 2026

  12. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of AGIOS PHARMACEUTICALS, INC. · Claim reviewed: May 16, 2026

  13. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Protara Therapeutics, Inc. · Claim reviewed: May 16, 2026

  14. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Spero Therapeutics, Inc. · Claim reviewed: May 16, 2026

  15. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Akebia Therapeutics, Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of AGIOS PHARMACEUTICALS, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Akebia Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Protara Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Spero Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Tvardi Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · CorroboratedBoard role: DirectorSupported by 5 public records5 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · CorroboratedCommittee assignments: CompensationSupported by 2 public records2 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Research/Innovation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources15 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  2. https://www.sec.gov/Archives/edgar/data/1346830/000110465926047695/tvrd-20260609xdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at Tvardi Therapeutics, Inc. (NASDAQ: TVRD)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  4. https://www.sec.gov/Archives/edgar/data/1517022/000151702225000023/akba-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Akebia Therapeutics, Inc. (NASDAQ: AKBA)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  6. https://www.sec.gov/Archives/edgar/data/1701108/000119312525100544/d797305ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Spero Therapeutics, Inc. (NASDAQ: SPRO)

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  9. https://www.sec.gov/Archives/edgar/data/1439222/000119312525096719/d838751ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO)

  10. https://www.sec.gov/Archives/edgar/data/1359931/000121390025035568/ea0239092-01.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Protara Therapeutics, Inc. (NASDAQ: TARA)

  11. https://www.sec.gov/Archives/edgar/data/1346830/000110465926047695/tvrd-20260609xdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  12. https://www.sec.gov/Archives/edgar/data/1439222/000119312525096719/d838751ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  13. https://www.sec.gov/Archives/edgar/data/1359931/000121390025035568/ea0239092-01.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  14. https://www.sec.gov/Archives/edgar/data/1701108/000119312525100544/d797305ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  15. https://www.sec.gov/Archives/edgar/data/1517022/000151702225000023/akba-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership